Immunic (IMUX) said Wednesday that interim data from a phase 2 trial show the potential effectiveness of its experimental drug vidofludimus calcium in progressive multiple sclerosis.
The company said the investigational drug was found to reduce neurofilament light chain levels compared with placebo in the study.
The company also said antiviral data suggested that the drug may reduce fatigue while preclinical data indicated that vidofludimus calcium promotes neuronal survival through the activation of nuclear receptor related 1, or Nurr1, and pathogenic T cell data support the drug's anti-inflammatory effects.
The data will be presented this week at a conference in Copenhagen, Denmark, Immunic said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。